OAC
OKUR

OMERS Administration Corp’s OnKure Therapeutics OKUR Stock Holding History

OMERS Administration Corp’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,100
Closed -$104K – 1146
2024
Q4 		$104K Buy
+12,100
New +$183K ﹤0.01% 906

Other funds holding OKUR

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OMERS Administration Corp's OKUR Position: Q1 2025 in Review

OMERS Administration Corp sold out of OnKure Therapeutics (OKUR) in Q1 2025, closing a stake of 12,100 shares — an estimated $104K sold.

OMERS Administration Corp first reported a position in OKUR in Q4 2024 and held it in 1 quarter. The position peaked at $104K in Q4 2024. 47 funds tracked by Wall St. Rank hold OKUR as of Q1 2025.

  • OMERS Administration Corp reported no remaining OnKure Therapeutics position as of Q1 2025 after selling out during the quarter.
  • OMERS Administration Corp sold 12,100 OnKure Therapeutics shares in Q1 2025, an estimated $104K.
  • OMERS Administration Corp first reported a position in OnKure Therapeutics in Q4 2024 and held it in 1 quarter.
  • OMERS Administration Corp's OnKure Therapeutics position peaked at $104K in Q4 2024.
  • 47 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2025.

Based on OMERS Administration Corp's 13F filing for Q1 2025, filed 14 May 2025.